-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, the executives of pharmaceutical companies have changed very frequently
.
Not long ago, it was reported that the whereabouts of Dr.
Huang Weijuan, a core technician who had just left BeiGene, was confirmed, and the cancer drug research and development company Prelude Therapeutics confirmed to appoint him as the company's Chief Medical Officer (CMO), starting from April 4, 2022.
(US local time)
.
In addition, Dr.
Weijuan Huang will also serve as President
.
In addition to Dr.
Huang Weijuan, since February 22, Mr.
Qian Wei has also been appointed as the general manager of Roche's China customer interaction business model-oncology field, responsible for Roche's oncology field (breast cancer treatment field, blood tumor treatment field, lung cancer treatment field and Digestive tract tumor treatment field, southwest ecological group, northwest ecological group) work
.
It is worth noting that in fact, Mr.
Qian Wei left Roche and joined Junshi Biotechnology at the end of June 2021
.
In addition to the successive resignations of executives from domestic companies, according to incomplete statistics, since February, at least 4 executives of foreign companies in China have left
.
For example, Zhu Tong, Vice President of AstraZeneca China and Head of Cardiovascular, Renal and Metabolism Division, has announced his departure, and his term will officially end on April 9, 2022; on February 28, Fresenius Kabi China announced that Yang Kai, the company's vice president and chief financial officer, decided to leave the company at the end of March 2022 to seek external career development opportunities; on February 24, the organizational structure of Abbott's core diagnostics business unit was adjusted.
President Tony Chan decided to seek external opportunities.
.
.
On the whole, the flow of talents in the medical world has become the norm
.
Of course, at this stage, the frequent news of personnel changes in pharmaceutical companies also shows from the side that China's pharmaceutical industry is going through a new round of transformation and pain
.
It should be noted that with the departure of a large number of executives, the number of foreign executives leaving after joining local pharmaceutical companies is obviously increasing
.
In this regard, the industry believes that for local pharmaceutical companies, although the company may have recruited high-level talents, how to retain them is also becoming an urgent problem to be solved.
.
After all, whether medical talents stay or stay is often determined by multi-level and complex decision-making.
Many foreign executives are employed in local pharmaceutical companies, and it is inevitable that there may be “unacceptable” situations such as values, culture, and capital, so they make the decision to leave.
.
In this context, it is urgent to consolidate the medical talent foundation and improve the overall level of medical education
.
It is understood that in order to better promote the development of the biopharmaceutical industry, in recent years, many places in China have actually begun to issue policies to strengthen the training and introduction of relevant talents
.
For example, Shanghai has pointed out earlier that it supports biopharmaceutical enterprises to introduce outstanding talents, recommends key enterprises as key institutions for talent introduction, and introduces non-Shanghai fresh graduates from colleges and universities as key support employers
.
Provide overseas high-level talents and teams with convenience for entry, exit and residence, and implement the relevant preferential tax policies for talents granted by the state to Shanghai
.
Guangdong proposes to speed up the construction of the Guangdong-Hong Kong-Macao Talent Cooperation Demonstration Zone, Shenzhen International Talent Special Zone, Guangzhou Nansha New Area International Talent Special Zone, create the International Academician Valley of the Hengqin Guangdong-Macao Deep Cooperation Zone, and the Sino-Singapore Guangzhou Knowledge City International Talent Free Port.
.
.
Disclaimer : Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
Not long ago, it was reported that the whereabouts of Dr.
Huang Weijuan, a core technician who had just left BeiGene, was confirmed, and the cancer drug research and development company Prelude Therapeutics confirmed to appoint him as the company's Chief Medical Officer (CMO), starting from April 4, 2022.
(US local time)
.
In addition, Dr.
Weijuan Huang will also serve as President
.
In addition to Dr.
Huang Weijuan, since February 22, Mr.
Qian Wei has also been appointed as the general manager of Roche's China customer interaction business model-oncology field, responsible for Roche's oncology field (breast cancer treatment field, blood tumor treatment field, lung cancer treatment field and Digestive tract tumor treatment field, southwest ecological group, northwest ecological group) work
.
It is worth noting that in fact, Mr.
Qian Wei left Roche and joined Junshi Biotechnology at the end of June 2021
.
In addition to the successive resignations of executives from domestic companies, according to incomplete statistics, since February, at least 4 executives of foreign companies in China have left
.
For example, Zhu Tong, Vice President of AstraZeneca China and Head of Cardiovascular, Renal and Metabolism Division, has announced his departure, and his term will officially end on April 9, 2022; on February 28, Fresenius Kabi China announced that Yang Kai, the company's vice president and chief financial officer, decided to leave the company at the end of March 2022 to seek external career development opportunities; on February 24, the organizational structure of Abbott's core diagnostics business unit was adjusted.
President Tony Chan decided to seek external opportunities.
.
.
On the whole, the flow of talents in the medical world has become the norm
.
Of course, at this stage, the frequent news of personnel changes in pharmaceutical companies also shows from the side that China's pharmaceutical industry is going through a new round of transformation and pain
.
It should be noted that with the departure of a large number of executives, the number of foreign executives leaving after joining local pharmaceutical companies is obviously increasing
.
In this regard, the industry believes that for local pharmaceutical companies, although the company may have recruited high-level talents, how to retain them is also becoming an urgent problem to be solved.
.
After all, whether medical talents stay or stay is often determined by multi-level and complex decision-making.
Many foreign executives are employed in local pharmaceutical companies, and it is inevitable that there may be “unacceptable” situations such as values, culture, and capital, so they make the decision to leave.
.
In this context, it is urgent to consolidate the medical talent foundation and improve the overall level of medical education
.
It is understood that in order to better promote the development of the biopharmaceutical industry, in recent years, many places in China have actually begun to issue policies to strengthen the training and introduction of relevant talents
.
For example, Shanghai has pointed out earlier that it supports biopharmaceutical enterprises to introduce outstanding talents, recommends key enterprises as key institutions for talent introduction, and introduces non-Shanghai fresh graduates from colleges and universities as key support employers
.
Provide overseas high-level talents and teams with convenience for entry, exit and residence, and implement the relevant preferential tax policies for talents granted by the state to Shanghai
.
Guangdong proposes to speed up the construction of the Guangdong-Hong Kong-Macao Talent Cooperation Demonstration Zone, Shenzhen International Talent Special Zone, Guangzhou Nansha New Area International Talent Special Zone, create the International Academician Valley of the Hengqin Guangdong-Macao Deep Cooperation Zone, and the Sino-Singapore Guangzhou Knowledge City International Talent Free Port.
.
.
Disclaimer : Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
